nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—ABCB1—Methylprednisolone—ankylosing spondylitis	0.125	0.279	CbGbCtD
Carfilzomib—ABCB1—Betamethasone—ankylosing spondylitis	0.0814	0.182	CbGbCtD
Carfilzomib—ABCB1—Prednisolone—ankylosing spondylitis	0.0803	0.179	CbGbCtD
Carfilzomib—ABCB1—Prednisone—ankylosing spondylitis	0.0758	0.169	CbGbCtD
Carfilzomib—ABCB1—Dexamethasone—ankylosing spondylitis	0.0473	0.106	CbGbCtD
Carfilzomib—ABCB1—Methotrexate—ankylosing spondylitis	0.038	0.0849	CbGbCtD
Carfilzomib—Tumour lysis syndrome—Methotrexate—ankylosing spondylitis	0.00365	0.0366	CcSEcCtD
Carfilzomib—PSMB8—Balsalazide—Sulfasalazine—ankylosing spondylitis	0.00364	0.134	CbGdCrCtD
Carfilzomib—PSMB9—Antigen processing-Cross presentation—HLA-B—ankylosing spondylitis	0.00322	0.00758	CbGpPWpGaD
Carfilzomib—PSMB1—Proteasome Degradation—HLA-B—ankylosing spondylitis	0.00301	0.00708	CbGpPWpGaD
Carfilzomib—PSMB5—Proteasome Degradation—HLA-B—ankylosing spondylitis	0.00301	0.00708	CbGpPWpGaD
Carfilzomib—PSMB2—Proteasome Degradation—HLA-B—ankylosing spondylitis	0.00301	0.00708	CbGpPWpGaD
Carfilzomib—PSMB10—Antigen processing-Cross presentation—HLA-A—ankylosing spondylitis	0.003	0.00706	CbGpPWpGaD
Carfilzomib—PSMB9—Antigen processing-Cross presentation—HLA-A—ankylosing spondylitis	0.00298	0.00702	CbGpPWpGaD
Carfilzomib—PSMB1—ER-Phagosome pathway—HLA-B—ankylosing spondylitis	0.00297	0.00699	CbGpPWpGaD
Carfilzomib—PSMB5—ER-Phagosome pathway—HLA-B—ankylosing spondylitis	0.00297	0.00699	CbGpPWpGaD
Carfilzomib—PSMB2—ER-Phagosome pathway—HLA-B—ankylosing spondylitis	0.00297	0.00699	CbGpPWpGaD
Carfilzomib—PSMB8—Proteasome Degradation—HLA-B—ankylosing spondylitis	0.00297	0.00698	CbGpPWpGaD
Carfilzomib—PSMB8—ER-Phagosome pathway—HLA-B—ankylosing spondylitis	0.00293	0.00689	CbGpPWpGaD
Carfilzomib—PSMB1—Class I MHC mediated antigen processing & presentation—ERAP1—ankylosing spondylitis	0.00288	0.00679	CbGpPWpGaD
Carfilzomib—PSMB5—Class I MHC mediated antigen processing & presentation—ERAP1—ankylosing spondylitis	0.00288	0.00679	CbGpPWpGaD
Carfilzomib—PSMB2—Class I MHC mediated antigen processing & presentation—ERAP1—ankylosing spondylitis	0.00288	0.00679	CbGpPWpGaD
Carfilzomib—PSMB8—Interferon alpha/beta signaling—HLA-B—ankylosing spondylitis	0.00286	0.00672	CbGpPWpGaD
Carfilzomib—PSMB8—Class I MHC mediated antigen processing & presentation—ERAP1—ankylosing spondylitis	0.00284	0.00669	CbGpPWpGaD
Carfilzomib—PSMB2—Proteasome Degradation—HLA-A—ankylosing spondylitis	0.00279	0.00656	CbGpPWpGaD
Carfilzomib—PSMB1—Proteasome Degradation—HLA-A—ankylosing spondylitis	0.00279	0.00656	CbGpPWpGaD
Carfilzomib—PSMB5—Proteasome Degradation—HLA-A—ankylosing spondylitis	0.00279	0.00656	CbGpPWpGaD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—IL1R2—ankylosing spondylitis	0.00276	0.00649	CbGpPWpGaD
Carfilzomib—PSMB5—ER-Phagosome pathway—HLA-A—ankylosing spondylitis	0.00275	0.00647	CbGpPWpGaD
Carfilzomib—PSMB1—ER-Phagosome pathway—HLA-A—ankylosing spondylitis	0.00275	0.00647	CbGpPWpGaD
Carfilzomib—PSMB2—ER-Phagosome pathway—HLA-A—ankylosing spondylitis	0.00275	0.00647	CbGpPWpGaD
Carfilzomib—PSMB8—Proteasome Degradation—HLA-A—ankylosing spondylitis	0.00275	0.00646	CbGpPWpGaD
Carfilzomib—PSMB8—ER-Phagosome pathway—HLA-A—ankylosing spondylitis	0.00271	0.00638	CbGpPWpGaD
Carfilzomib—PSMB8—Interferon alpha/beta signaling—HLA-A—ankylosing spondylitis	0.00265	0.00622	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.00249	0.00585	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.00249	0.00585	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.00249	0.00585	CbGpPWpGaD
Carfilzomib—PSMB2—Antigen processing-Cross presentation—HLA-B—ankylosing spondylitis	0.00245	0.00577	CbGpPWpGaD
Carfilzomib—PSMB1—Antigen processing-Cross presentation—HLA-B—ankylosing spondylitis	0.00245	0.00577	CbGpPWpGaD
Carfilzomib—PSMB5—Antigen processing-Cross presentation—HLA-B—ankylosing spondylitis	0.00245	0.00577	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.00245	0.00577	CbGpPWpGaD
Carfilzomib—PSMB8—Antigen processing-Cross presentation—HLA-B—ankylosing spondylitis	0.00242	0.00569	CbGpPWpGaD
Carfilzomib—Lymphopenia—Prednisone—ankylosing spondylitis	0.00237	0.0238	CcSEcCtD
Carfilzomib—PSMB1—Antigen processing-Cross presentation—HLA-A—ankylosing spondylitis	0.00227	0.00535	CbGpPWpGaD
Carfilzomib—PSMB5—Antigen processing-Cross presentation—HLA-A—ankylosing spondylitis	0.00227	0.00535	CbGpPWpGaD
Carfilzomib—PSMB2—Antigen processing-Cross presentation—HLA-A—ankylosing spondylitis	0.00227	0.00535	CbGpPWpGaD
Carfilzomib—PSMB8—Interferon Signaling—HLA-C—ankylosing spondylitis	0.00225	0.00529	CbGpPWpGaD
Carfilzomib—PSMB8—Antigen processing-Cross presentation—HLA-A—ankylosing spondylitis	0.00224	0.00527	CbGpPWpGaD
Carfilzomib—Neuritis—Prednisolone—ankylosing spondylitis	0.00224	0.0224	CcSEcCtD
Carfilzomib—Hypercalcaemia—Methylprednisolone—ankylosing spondylitis	0.0022	0.0221	CcSEcCtD
Carfilzomib—Bacterial infection—Methotrexate—ankylosing spondylitis	0.0022	0.022	CcSEcCtD
Carfilzomib—PSMB10—Class I MHC mediated antigen processing & presentation—HLA-C—ankylosing spondylitis	0.00219	0.00514	CbGpPWpGaD
Carfilzomib—PSMB9—Class I MHC mediated antigen processing & presentation—HLA-C—ankylosing spondylitis	0.00218	0.00512	CbGpPWpGaD
Carfilzomib—PSMB10—Host Interactions of HIV factors—HLA-A—ankylosing spondylitis	0.00209	0.00491	CbGpPWpGaD
Carfilzomib—PSMB9—Host Interactions of HIV factors—HLA-A—ankylosing spondylitis	0.00208	0.00488	CbGpPWpGaD
Carfilzomib—Neuritis—Triamcinolone—ankylosing spondylitis	0.00206	0.0206	CcSEcCtD
Carfilzomib—Neuritis—Methylprednisolone—ankylosing spondylitis	0.00205	0.0206	CcSEcCtD
Carfilzomib—PSMB10—B Cell Activation—CD79A—ankylosing spondylitis	0.00205	0.00482	CbGpPWpGaD
Carfilzomib—PSMB9—B Cell Activation—CD79A—ankylosing spondylitis	0.00204	0.00479	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—KIR3DL1—ankylosing spondylitis	0.00199	0.00468	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—KIR3DL1—ankylosing spondylitis	0.00198	0.00466	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.00188	0.00443	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.00187	0.00441	CbGpPWpGaD
Carfilzomib—Neuritis—Dexamethasone—ankylosing spondylitis	0.00187	0.0187	CcSEcCtD
Carfilzomib—Neuritis—Betamethasone—ankylosing spondylitis	0.00187	0.0187	CcSEcCtD
Carfilzomib—PSMB5—Class I MHC mediated antigen processing & presentation—HLA-C—ankylosing spondylitis	0.00166	0.0039	CbGpPWpGaD
Carfilzomib—PSMB1—Class I MHC mediated antigen processing & presentation—HLA-C—ankylosing spondylitis	0.00166	0.0039	CbGpPWpGaD
Carfilzomib—PSMB2—Class I MHC mediated antigen processing & presentation—HLA-C—ankylosing spondylitis	0.00166	0.0039	CbGpPWpGaD
Carfilzomib—PSMB8—Class I MHC mediated antigen processing & presentation—HLA-C—ankylosing spondylitis	0.00163	0.00384	CbGpPWpGaD
Carfilzomib—Neuritis—Prednisone—ankylosing spondylitis	0.00162	0.0163	CcSEcCtD
Carfilzomib—PSMB2—Host Interactions of HIV factors—HLA-A—ankylosing spondylitis	0.00158	0.00372	CbGpPWpGaD
Carfilzomib—PSMB5—Host Interactions of HIV factors—HLA-A—ankylosing spondylitis	0.00158	0.00372	CbGpPWpGaD
Carfilzomib—PSMB1—Host Interactions of HIV factors—HLA-A—ankylosing spondylitis	0.00158	0.00372	CbGpPWpGaD
Carfilzomib—PSMB8—Host Interactions of HIV factors—HLA-A—ankylosing spondylitis	0.00156	0.00367	CbGpPWpGaD
Carfilzomib—PSMB5—B Cell Activation—CD79A—ankylosing spondylitis	0.00155	0.00365	CbGpPWpGaD
Carfilzomib—PSMB1—B Cell Activation—CD79A—ankylosing spondylitis	0.00155	0.00365	CbGpPWpGaD
Carfilzomib—PSMB2—B Cell Activation—CD79A—ankylosing spondylitis	0.00155	0.00365	CbGpPWpGaD
Carfilzomib—PSMB8—B Cell Activation—CD79A—ankylosing spondylitis	0.00153	0.0036	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—KIR3DL1—ankylosing spondylitis	0.00151	0.00355	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—KIR3DL1—ankylosing spondylitis	0.00151	0.00355	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—KIR3DL1—ankylosing spondylitis	0.00151	0.00355	CbGpPWpGaD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—HLA-C—ankylosing spondylitis	0.0015	0.00353	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—KIR3DL1—ankylosing spondylitis	0.00149	0.0035	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.00143	0.00336	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.00143	0.00336	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.00143	0.00336	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.00141	0.00331	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—ANTXR2—ankylosing spondylitis	0.00139	0.00327	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—ANTXR2—ankylosing spondylitis	0.00139	0.00326	CbGpPWpGaD
Carfilzomib—PSMB10—HIV Infection—HLA-A—ankylosing spondylitis	0.00135	0.00319	CbGpPWpGaD
Carfilzomib—PSMB9—HIV Infection—HLA-A—ankylosing spondylitis	0.00135	0.00317	CbGpPWpGaD
Carfilzomib—Cardiac failure congestive—Prednisolone—ankylosing spondylitis	0.00134	0.0134	CcSEcCtD
Carfilzomib—PSMB8—Interferon Signaling—HLA-B—ankylosing spondylitis	0.00133	0.00313	CbGpPWpGaD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	0.0013	0.00307	CbGpPWpGaD
Carfilzomib—PSMB10—Class I MHC mediated antigen processing & presentation—HLA-B—ankylosing spondylitis	0.00129	0.00304	CbGpPWpGaD
Carfilzomib—PSMB9—Class I MHC mediated antigen processing & presentation—HLA-B—ankylosing spondylitis	0.00129	0.00303	CbGpPWpGaD
Carfilzomib—PSMB9—Dexamethasone—Methylprednisolone—ankylosing spondylitis	0.00125	0.0459	CbGdCrCtD
Carfilzomib—PSMB9—Betamethasone—Methylprednisolone—ankylosing spondylitis	0.00125	0.0459	CbGdCrCtD
Carfilzomib—ABCB1—Allograft Rejection—HLA-C—ankylosing spondylitis	0.00123	0.0029	CbGpPWpGaD
Carfilzomib—PSMB8—Interferon Signaling—HLA-A—ankylosing spondylitis	0.00123	0.0029	CbGpPWpGaD
Carfilzomib—Cardiac failure congestive—Triamcinolone—ankylosing spondylitis	0.00123	0.0123	CcSEcCtD
Carfilzomib—PSMB9—Dexamethasone—Betamethasone—ankylosing spondylitis	0.00123	0.0452	CbGdCrCtD
Carfilzomib—PSMB9—Betamethasone—Dexamethasone—ankylosing spondylitis	0.00123	0.0452	CbGdCrCtD
Carfilzomib—Cardiac failure congestive—Methylprednisolone—ankylosing spondylitis	0.00123	0.0123	CcSEcCtD
Carfilzomib—PSMB10—Immune System—IL1R2—ankylosing spondylitis	0.00121	0.00284	CbGpPWpGaD
Carfilzomib—PSMB9—Dexamethasone—Triamcinolone—ankylosing spondylitis	0.0012	0.0441	CbGdCrCtD
Carfilzomib—PSMB9—Betamethasone—Triamcinolone—ankylosing spondylitis	0.0012	0.0441	CbGdCrCtD
Carfilzomib—PSMB9—Immune System—IL1R2—ankylosing spondylitis	0.0012	0.00282	CbGpPWpGaD
Carfilzomib—PSMB10—Class I MHC mediated antigen processing & presentation—HLA-A—ankylosing spondylitis	0.0012	0.00282	CbGpPWpGaD
Carfilzomib—PSMB9—Class I MHC mediated antigen processing & presentation—HLA-A—ankylosing spondylitis	0.00119	0.0028	CbGpPWpGaD
Carfilzomib—Cardiac arrest—Prednisolone—ankylosing spondylitis	0.00115	0.0116	CcSEcCtD
Carfilzomib—PSMB10—Immune System—ERAP1—ankylosing spondylitis	0.00114	0.00269	CbGpPWpGaD
Carfilzomib—PSMB9—Betamethasone—Prednisone—ankylosing spondylitis	0.00114	0.0419	CbGdCrCtD
Carfilzomib—PSMB9—Dexamethasone—Prednisone—ankylosing spondylitis	0.00114	0.0419	CbGdCrCtD
Carfilzomib—PSMB9—Immune System—ERAP1—ankylosing spondylitis	0.00114	0.00268	CbGpPWpGaD
Carfilzomib—ABCB1—Allograft Rejection—IL17A—ankylosing spondylitis	0.00113	0.00265	CbGpPWpGaD
Carfilzomib—Cardiac failure congestive—Betamethasone—ankylosing spondylitis	0.00111	0.0112	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Dexamethasone—ankylosing spondylitis	0.00111	0.0112	CcSEcCtD
Carfilzomib—PSMB9—Betamethasone—Prednisolone—ankylosing spondylitis	0.00111	0.0409	CbGdCrCtD
Carfilzomib—PSMB9—Dexamethasone—Prednisolone—ankylosing spondylitis	0.00111	0.0409	CbGdCrCtD
Carfilzomib—PSMB10—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.00108	0.00255	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.00108	0.00253	CbGpPWpGaD
Carfilzomib—Cardiac arrest—Triamcinolone—ankylosing spondylitis	0.00106	0.0106	CcSEcCtD
Carfilzomib—Cardiac arrest—Methylprednisolone—ankylosing spondylitis	0.00106	0.0106	CcSEcCtD
Carfilzomib—PSMB1—Disease—ANTXR2—ankylosing spondylitis	0.00105	0.00248	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—ANTXR2—ankylosing spondylitis	0.00105	0.00248	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—ANTXR2—ankylosing spondylitis	0.00105	0.00248	CbGpPWpGaD
Carfilzomib—Sepsis—Prednisone—ankylosing spondylitis	0.00105	0.0106	CcSEcCtD
Carfilzomib—ABCB1—Allograft Rejection—IL12B—ankylosing spondylitis	0.00105	0.00247	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—CARD9—ankylosing spondylitis	0.00104	0.00246	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—ANTXR2—ankylosing spondylitis	0.00104	0.00245	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—CARD9—ankylosing spondylitis	0.00104	0.00245	CbGpPWpGaD
Carfilzomib—PSMB1—HIV Infection—HLA-A—ankylosing spondylitis	0.00103	0.00242	CbGpPWpGaD
Carfilzomib—PSMB2—HIV Infection—HLA-A—ankylosing spondylitis	0.00103	0.00242	CbGpPWpGaD
Carfilzomib—PSMB5—HIV Infection—HLA-A—ankylosing spondylitis	0.00103	0.00242	CbGpPWpGaD
Carfilzomib—PSMB8—HIV Infection—HLA-A—ankylosing spondylitis	0.00101	0.00238	CbGpPWpGaD
Carfilzomib—PSMB1—Class I MHC mediated antigen processing & presentation—HLA-B—ankylosing spondylitis	0.00098	0.0023	CbGpPWpGaD
Carfilzomib—PSMB2—Class I MHC mediated antigen processing & presentation—HLA-B—ankylosing spondylitis	0.00098	0.0023	CbGpPWpGaD
Carfilzomib—PSMB5—Class I MHC mediated antigen processing & presentation—HLA-B—ankylosing spondylitis	0.00098	0.0023	CbGpPWpGaD
Carfilzomib—PSMB8—Medrysone—Methylprednisolone—ankylosing spondylitis	0.000975	0.0358	CbGdCrCtD
Carfilzomib—Cardiac failure congestive—Prednisone—ankylosing spondylitis	0.000971	0.00974	CcSEcCtD
Carfilzomib—PSMB8—Class I MHC mediated antigen processing & presentation—HLA-B—ankylosing spondylitis	0.000966	0.00227	CbGpPWpGaD
Carfilzomib—Cardiac arrest—Betamethasone—ankylosing spondylitis	0.000961	0.00964	CcSEcCtD
Carfilzomib—Cardiac arrest—Dexamethasone—ankylosing spondylitis	0.000961	0.00964	CcSEcCtD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.000939	0.00221	CbGpPWpGaD
Carfilzomib—Acute coronary syndrome—Prednisolone—ankylosing spondylitis	0.000921	0.00923	CcSEcCtD
Carfilzomib—Hypokalaemia—Betamethasone—ankylosing spondylitis	0.00092	0.00923	CcSEcCtD
Carfilzomib—Hypokalaemia—Dexamethasone—ankylosing spondylitis	0.00092	0.00923	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Prednisolone—ankylosing spondylitis	0.000915	0.00918	CcSEcCtD
Carfilzomib—PSMB5—Immune System—IL1R2—ankylosing spondylitis	0.000913	0.00215	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL1R2—ankylosing spondylitis	0.000913	0.00215	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL1R2—ankylosing spondylitis	0.000913	0.00215	CbGpPWpGaD
Carfilzomib—PSMB5—Class I MHC mediated antigen processing & presentation—HLA-A—ankylosing spondylitis	0.000908	0.00214	CbGpPWpGaD
Carfilzomib—PSMB1—Class I MHC mediated antigen processing & presentation—HLA-A—ankylosing spondylitis	0.000908	0.00214	CbGpPWpGaD
Carfilzomib—PSMB2—Class I MHC mediated antigen processing & presentation—HLA-A—ankylosing spondylitis	0.000908	0.00214	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL1R2—ankylosing spondylitis	0.0009	0.00212	CbGpPWpGaD
Carfilzomib—Upper respiratory tract infection—Triamcinolone—ankylosing spondylitis	0.000895	0.00898	CcSEcCtD
Carfilzomib—PSMB8—Class I MHC mediated antigen processing & presentation—HLA-A—ankylosing spondylitis	0.000895	0.00211	CbGpPWpGaD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000888	0.00209	CbGpPWpGaD
Carfilzomib—Sepsis—Methotrexate—ankylosing spondylitis	0.00088	0.00882	CcSEcCtD
Carfilzomib—PSMB8—Medrysone—Prednisolone—ankylosing spondylitis	0.000868	0.0319	CbGdCrCtD
Carfilzomib—PSMB1—Immune System—ERAP1—ankylosing spondylitis	0.000866	0.00204	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—ERAP1—ankylosing spondylitis	0.000866	0.00204	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—ERAP1—ankylosing spondylitis	0.000866	0.00204	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—ERAP1—ankylosing spondylitis	0.000854	0.00201	CbGpPWpGaD
Carfilzomib—Acute coronary syndrome—Triamcinolone—ankylosing spondylitis	0.000847	0.00849	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Methylprednisolone—ankylosing spondylitis	0.000845	0.00847	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Triamcinolone—ankylosing spondylitis	0.000842	0.00844	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Methylprednisolone—ankylosing spondylitis	0.00084	0.00842	CcSEcCtD
Carfilzomib—Cardiac arrest—Prednisone—ankylosing spondylitis	0.000837	0.0084	CcSEcCtD
Carfilzomib—PSMB10—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000825	0.00194	CbGpPWpGaD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000822	0.00194	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000821	0.00193	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—B3GNT2—ankylosing spondylitis	0.00082	0.00193	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.00082	0.00193	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.00082	0.00193	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.00082	0.00193	CbGpPWpGaD
Carfilzomib—Hepatic failure—Methotrexate—ankylosing spondylitis	0.000819	0.00821	CcSEcCtD
Carfilzomib—PSMB9—Disease—B3GNT2—ankylosing spondylitis	0.000816	0.00192	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000808	0.0019	CbGpPWpGaD
Carfilzomib—Hypokalaemia—Prednisone—ankylosing spondylitis	0.000801	0.00804	CcSEcCtD
Carfilzomib—Renal failure acute—Methotrexate—ankylosing spondylitis	0.000797	0.00799	CcSEcCtD
Carfilzomib—PSMB1—Immune System—CARD9—ankylosing spondylitis	0.000792	0.00186	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CARD9—ankylosing spondylitis	0.000792	0.00186	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CARD9—ankylosing spondylitis	0.000792	0.00186	CbGpPWpGaD
Carfilzomib—Hyperglycaemia—Dexamethasone—ankylosing spondylitis	0.000788	0.00791	CcSEcCtD
Carfilzomib—Hyperglycaemia—Betamethasone—ankylosing spondylitis	0.000788	0.00791	CcSEcCtD
Carfilzomib—PSMB8—Immune System—CARD9—ankylosing spondylitis	0.000781	0.00184	CbGpPWpGaD
Carfilzomib—ABCB1—Allograft Rejection—IL1A—ankylosing spondylitis	0.000771	0.00181	CbGpPWpGaD
Carfilzomib—Acute coronary syndrome—Betamethasone—ankylosing spondylitis	0.000768	0.0077	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Dexamethasone—ankylosing spondylitis	0.000768	0.0077	CcSEcCtD
Carfilzomib—ABCB1—Allograft Rejection—IL10—ankylosing spondylitis	0.000766	0.0018	CbGpPWpGaD
Carfilzomib—ABCB1—Allograft Rejection—CD40LG—ankylosing spondylitis	0.000766	0.0018	CbGpPWpGaD
Carfilzomib—Neuropathy peripheral—Dexamethasone—ankylosing spondylitis	0.000764	0.00766	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Betamethasone—ankylosing spondylitis	0.000764	0.00766	CcSEcCtD
Carfilzomib—PSMB10—Apoptosis—TNF—ankylosing spondylitis	0.000763	0.0018	CbGpPWpGaD
Carfilzomib—PSMB9—Apoptosis—TNF—ankylosing spondylitis	0.000759	0.00179	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000732	0.00172	CbGpPWpGaD
Carfilzomib—ABCB1—Allograft Rejection—HLA-B—ankylosing spondylitis	0.000729	0.00172	CbGpPWpGaD
Carfilzomib—Cardiac disorder—Methylprednisolone—ankylosing spondylitis	0.000714	0.00716	CcSEcCtD
Carfilzomib—Neutropenia—Prednisone—ankylosing spondylitis	0.000712	0.00714	CcSEcCtD
Carfilzomib—PSMB8—Fluorometholone—Methylprednisolone—ankylosing spondylitis	0.000706	0.0259	CbGdCrCtD
Carfilzomib—PSMB8—Fluorometholone—Betamethasone—ankylosing spondylitis	0.000694	0.0255	CbGdCrCtD
Carfilzomib—PSMB8—Fluorometholone—Dexamethasone—ankylosing spondylitis	0.000694	0.0255	CbGdCrCtD
Carfilzomib—PSMB10—Metabolism—B3GNT2—ankylosing spondylitis	0.000687	0.00162	CbGpPWpGaD
Carfilzomib—Hyperglycaemia—Prednisone—ankylosing spondylitis	0.000687	0.00688	CcSEcCtD
Carfilzomib—PSMB9—Metabolism—B3GNT2—ankylosing spondylitis	0.000684	0.00161	CbGpPWpGaD
Carfilzomib—PSMB8—Fluorometholone—Triamcinolone—ankylosing spondylitis	0.000679	0.0249	CbGdCrCtD
Carfilzomib—ABCB1—Allograft Rejection—HLA-A—ankylosing spondylitis	0.000675	0.00159	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000673	0.00158	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000669	0.00158	CbGpPWpGaD
Carfilzomib—Acute coronary syndrome—Prednisone—ankylosing spondylitis	0.000669	0.00671	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Prednisone—ankylosing spondylitis	0.000665	0.00667	CcSEcCtD
Carfilzomib—PSMB10—Immune System—HLA-C—ankylosing spondylitis	0.000656	0.00154	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—HLA-C—ankylosing spondylitis	0.000653	0.00154	CbGpPWpGaD
Carfilzomib—Back pain—Triamcinolone—ankylosing spondylitis	0.000649	0.00651	CcSEcCtD
Carfilzomib—PSMB8—Fluorometholone—Prednisone—ankylosing spondylitis	0.000644	0.0237	CbGdCrCtD
Carfilzomib—PSMB10—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.00064	0.00151	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000637	0.0015	CbGpPWpGaD
Carfilzomib—Hypertension—Prednisolone—ankylosing spondylitis	0.00063	0.00632	CcSEcCtD
Carfilzomib—PSMB8—Fluorometholone—Prednisolone—ankylosing spondylitis	0.000629	0.0231	CbGdCrCtD
Carfilzomib—PSMB2—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000625	0.00147	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000625	0.00147	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000625	0.00147	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—B3GNT2—ankylosing spondylitis	0.000622	0.00146	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—B3GNT2—ankylosing spondylitis	0.000622	0.00146	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—B3GNT2—ankylosing spondylitis	0.000622	0.00146	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000616	0.00145	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—B3GNT2—ankylosing spondylitis	0.000613	0.00144	CbGpPWpGaD
Carfilzomib—Neutropenia—Methotrexate—ankylosing spondylitis	0.000595	0.00596	CcSEcCtD
Carfilzomib—PSMB10—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000593	0.00139	CbGpPWpGaD
Carfilzomib—Upper respiratory tract infection—Methotrexate—ankylosing spondylitis	0.000591	0.00593	CcSEcCtD
Carfilzomib—PSMB9—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.00059	0.00139	CbGpPWpGaD
Carfilzomib—Cough—Triamcinolone—ankylosing spondylitis	0.000586	0.00587	CcSEcCtD
Carfilzomib—Hypertension—Triamcinolone—ankylosing spondylitis	0.000579	0.00581	CcSEcCtD
Carfilzomib—PSMB5—Apoptosis—TNF—ankylosing spondylitis	0.000578	0.00136	CbGpPWpGaD
Carfilzomib—PSMB2—Apoptosis—TNF—ankylosing spondylitis	0.000578	0.00136	CbGpPWpGaD
Carfilzomib—PSMB1—Apoptosis—TNF—ankylosing spondylitis	0.000578	0.00136	CbGpPWpGaD
Carfilzomib—Hypertension—Methylprednisolone—ankylosing spondylitis	0.000578	0.0058	CcSEcCtD
Carfilzomib—Pneumonia—Methotrexate—ankylosing spondylitis	0.00057	0.00572	CcSEcCtD
Carfilzomib—Arthralgia—Methylprednisolone—ankylosing spondylitis	0.00057	0.00572	CcSEcCtD
Carfilzomib—PSMB8—Apoptosis—TNF—ankylosing spondylitis	0.00057	0.00134	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL1RN—ankylosing spondylitis	0.00057	0.00134	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL1RN—ankylosing spondylitis	0.000567	0.00133	CbGpPWpGaD
Carfilzomib—Renal failure—Methotrexate—ankylosing spondylitis	0.000557	0.00559	CcSEcCtD
Carfilzomib—Infection—Triamcinolone—ankylosing spondylitis	0.000544	0.00546	CcSEcCtD
Carfilzomib—Infection—Methylprednisolone—ankylosing spondylitis	0.000543	0.00544	CcSEcCtD
Carfilzomib—Insomnia—Prednisolone—ankylosing spondylitis	0.000539	0.0054	CcSEcCtD
Carfilzomib—PSMB8—Diflorasone—Methylprednisolone—ankylosing spondylitis	0.000537	0.0198	CbGdCrCtD
Carfilzomib—PSMB8—Diflorasone—Dexamethasone—ankylosing spondylitis	0.000529	0.0194	CbGdCrCtD
Carfilzomib—PSMB8—Diflorasone—Betamethasone—ankylosing spondylitis	0.000529	0.0194	CbGdCrCtD
Carfilzomib—Hypertension—Dexamethasone—ankylosing spondylitis	0.000526	0.00527	CcSEcCtD
Carfilzomib—Hypertension—Betamethasone—ankylosing spondylitis	0.000526	0.00527	CcSEcCtD
Carfilzomib—PSMB2—Metabolism—B3GNT2—ankylosing spondylitis	0.000521	0.00123	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—B3GNT2—ankylosing spondylitis	0.000521	0.00123	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—B3GNT2—ankylosing spondylitis	0.000521	0.00123	CbGpPWpGaD
Carfilzomib—PSMB8—Diflorasone—Triamcinolone—ankylosing spondylitis	0.000517	0.019	CbGdCrCtD
Carfilzomib—PSMB8—Metabolism—B3GNT2—ankylosing spondylitis	0.000513	0.00121	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.00051	0.0012	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.00051	0.0012	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.00051	0.0012	CbGpPWpGaD
Carfilzomib—Pain—Prednisolone—ankylosing spondylitis	0.000509	0.00511	CcSEcCtD
Carfilzomib—PSMB8—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000503	0.00118	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—CD79A—ankylosing spondylitis	0.0005	0.00118	CbGpPWpGaD
Carfilzomib—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000499	0.005	CcSEcCtD
Carfilzomib—PSMB9—Immune System—CD79A—ankylosing spondylitis	0.000498	0.00117	CbGpPWpGaD
Carfilzomib—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000498	0.00499	CcSEcCtD
Carfilzomib—PSMB5—Immune System—HLA-C—ankylosing spondylitis	0.000497	0.00117	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HLA-C—ankylosing spondylitis	0.000497	0.00117	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HLA-C—ankylosing spondylitis	0.000497	0.00117	CbGpPWpGaD
Carfilzomib—Insomnia—Triamcinolone—ankylosing spondylitis	0.000495	0.00497	CcSEcCtD
Carfilzomib—Insomnia—Methylprednisolone—ankylosing spondylitis	0.000494	0.00496	CcSEcCtD
Carfilzomib—Infection—Dexamethasone—ankylosing spondylitis	0.000494	0.00495	CcSEcCtD
Carfilzomib—Infection—Betamethasone—ankylosing spondylitis	0.000494	0.00495	CcSEcCtD
Carfilzomib—PSMB8—Diflorasone—Prednisone—ankylosing spondylitis	0.00049	0.018	CbGdCrCtD
Carfilzomib—PSMB8—Immune System—HLA-C—ankylosing spondylitis	0.00049	0.00115	CbGpPWpGaD
Carfilzomib—Anaemia—Prednisone—ankylosing spondylitis	0.00049	0.00492	CcSEcCtD
Carfilzomib—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000488	0.0049	CcSEcCtD
Carfilzomib—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000487	0.00488	CcSEcCtD
Carfilzomib—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000487	0.00488	CcSEcCtD
Carfilzomib—PSMB5—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000485	0.00114	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000485	0.00114	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000485	0.00114	CbGpPWpGaD
Carfilzomib—PSMB8—Diflorasone—Prednisolone—ankylosing spondylitis	0.000479	0.0176	CbGdCrCtD
Carfilzomib—PSMB8—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000478	0.00112	CbGpPWpGaD
Carfilzomib—Anorexia—Betamethasone—ankylosing spondylitis	0.000474	0.00475	CcSEcCtD
Carfilzomib—Anorexia—Dexamethasone—ankylosing spondylitis	0.000474	0.00475	CcSEcCtD
Carfilzomib—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.000472	0.00474	CcSEcCtD
Carfilzomib—Fatigue—Triamcinolone—ankylosing spondylitis	0.000472	0.00474	CcSEcCtD
Carfilzomib—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000471	0.00472	CcSEcCtD
Carfilzomib—Pain—Triamcinolone—ankylosing spondylitis	0.000468	0.0047	CcSEcCtD
Carfilzomib—Hypertension—Prednisone—ankylosing spondylitis	0.000458	0.00459	CcSEcCtD
Carfilzomib—Chills—Methotrexate—ankylosing spondylitis	0.000457	0.00458	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.000453	0.00454	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.000453	0.00454	CcSEcCtD
Carfilzomib—Arthralgia—Prednisone—ankylosing spondylitis	0.000451	0.00453	CcSEcCtD
Carfilzomib—Insomnia—Betamethasone—ankylosing spondylitis	0.000449	0.00451	CcSEcCtD
Carfilzomib—Insomnia—Dexamethasone—ankylosing spondylitis	0.000449	0.00451	CcSEcCtD
Carfilzomib—PSMB2—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000449	0.00106	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000449	0.00106	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000449	0.00106	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000443	0.00104	CbGpPWpGaD
Carfilzomib—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000433	0.00434	CcSEcCtD
Carfilzomib—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000432	0.00433	CcSEcCtD
Carfilzomib—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000432	0.00433	CcSEcCtD
Carfilzomib—PSMB5—Immune System—IL1RN—ankylosing spondylitis	0.000432	0.00102	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL1RN—ankylosing spondylitis	0.000432	0.00102	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL1RN—ankylosing spondylitis	0.000432	0.00102	CbGpPWpGaD
Carfilzomib—Infection—Prednisone—ankylosing spondylitis	0.00043	0.00431	CcSEcCtD
Carfilzomib—Back pain—Methotrexate—ankylosing spondylitis	0.000429	0.0043	CcSEcCtD
Carfilzomib—Fatigue—Dexamethasone—ankylosing spondylitis	0.000428	0.0043	CcSEcCtD
Carfilzomib—Fatigue—Betamethasone—ankylosing spondylitis	0.000428	0.0043	CcSEcCtD
Carfilzomib—PSMB8—Immune System—IL1RN—ankylosing spondylitis	0.000426	0.001	CbGpPWpGaD
Carfilzomib—Pain—Dexamethasone—ankylosing spondylitis	0.000425	0.00426	CcSEcCtD
Carfilzomib—Pain—Betamethasone—ankylosing spondylitis	0.000425	0.00426	CcSEcCtD
Carfilzomib—Anorexia—Prednisone—ankylosing spondylitis	0.000413	0.00414	CcSEcCtD
Carfilzomib—PSMB10—Immune System—IL1A—ankylosing spondylitis	0.00041	0.000965	CbGpPWpGaD
Carfilzomib—Anaemia—Methotrexate—ankylosing spondylitis	0.00041	0.00411	CcSEcCtD
Carfilzomib—PSMB9—Immune System—IL1A—ankylosing spondylitis	0.000408	0.000961	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—CD40LG—ankylosing spondylitis	0.000408	0.00096	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—CD40LG—ankylosing spondylitis	0.000406	0.000955	CbGpPWpGaD
Carfilzomib—Leukopenia—Methotrexate—ankylosing spondylitis	0.000397	0.00398	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.000394	0.00395	CcSEcCtD
Carfilzomib—PSMB10—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000394	0.000927	CbGpPWpGaD
Carfilzomib—Dizziness—Prednisolone—ankylosing spondylitis	0.000394	0.00395	CcSEcCtD
Carfilzomib—Asthenia—Triamcinolone—ankylosing spondylitis	0.000393	0.00394	CcSEcCtD
Carfilzomib—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000393	0.00394	CcSEcCtD
Carfilzomib—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000393	0.00394	CcSEcCtD
Carfilzomib—PSMB9—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000392	0.000923	CbGpPWpGaD
Carfilzomib—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000392	0.00393	CcSEcCtD
Carfilzomib—Insomnia—Prednisone—ankylosing spondylitis	0.000391	0.00393	CcSEcCtD
Carfilzomib—PSMB10—Immune System—HLA-B—ankylosing spondylitis	0.000388	0.000913	CbGpPWpGaD
Carfilzomib—Cough—Methotrexate—ankylosing spondylitis	0.000387	0.00388	CcSEcCtD
Carfilzomib—PSMB9—Immune System—HLA-B—ankylosing spondylitis	0.000386	0.000909	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CD79A—ankylosing spondylitis	0.000379	0.000892	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CD79A—ankylosing spondylitis	0.000379	0.000892	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CD79A—ankylosing spondylitis	0.000379	0.000892	CbGpPWpGaD
Carfilzomib—Arthralgia—Methotrexate—ankylosing spondylitis	0.000377	0.00378	CcSEcCtD
Carfilzomib—Decreased appetite—Prednisone—ankylosing spondylitis	0.000376	0.00377	CcSEcCtD
Carfilzomib—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000374	0.00375	CcSEcCtD
Carfilzomib—PSMB8—Immune System—CD79A—ankylosing spondylitis	0.000374	0.00088	CbGpPWpGaD
Carfilzomib—Fatigue—Prednisone—ankylosing spondylitis	0.000373	0.00374	CcSEcCtD
Carfilzomib—Headache—Prednisolone—ankylosing spondylitis	0.000373	0.00374	CcSEcCtD
Carfilzomib—Constipation—Prednisone—ankylosing spondylitis	0.00037	0.00371	CcSEcCtD
Carfilzomib—Dizziness—Triamcinolone—ankylosing spondylitis	0.000362	0.00363	CcSEcCtD
Carfilzomib—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000361	0.00362	CcSEcCtD
Carfilzomib—PSMB10—Immune System—HLA-A—ankylosing spondylitis	0.00036	0.000846	CbGpPWpGaD
Carfilzomib—Infection—Methotrexate—ankylosing spondylitis	0.000359	0.0036	CcSEcCtD
Carfilzomib—PSMB9—Immune System—HLA-A—ankylosing spondylitis	0.000358	0.000842	CbGpPWpGaD
Carfilzomib—Asthenia—Dexamethasone—ankylosing spondylitis	0.000357	0.00358	CcSEcCtD
Carfilzomib—Asthenia—Betamethasone—ankylosing spondylitis	0.000357	0.00358	CcSEcCtD
Carfilzomib—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.000354	0.00355	CcSEcCtD
Carfilzomib—Nausea—Prednisolone—ankylosing spondylitis	0.000354	0.00355	CcSEcCtD
Carfilzomib—Vomiting—Triamcinolone—ankylosing spondylitis	0.000348	0.00349	CcSEcCtD
Carfilzomib—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000347	0.00348	CcSEcCtD
Carfilzomib—Anorexia—Methotrexate—ankylosing spondylitis	0.000345	0.00346	CcSEcCtD
Carfilzomib—Headache—Triamcinolone—ankylosing spondylitis	0.000343	0.00344	CcSEcCtD
Carfilzomib—PSMB10—Immune System—CRP—ankylosing spondylitis	0.000343	0.000807	CbGpPWpGaD
Carfilzomib—Headache—Methylprednisolone—ankylosing spondylitis	0.000342	0.00343	CcSEcCtD
Carfilzomib—Body temperature increased—Prednisone—ankylosing spondylitis	0.000342	0.00343	CcSEcCtD
Carfilzomib—PSMB9—Immune System—CRP—ankylosing spondylitis	0.000341	0.000803	CbGpPWpGaD
Carfilzomib—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.00034	0.00341	CcSEcCtD
Carfilzomib—Diarrhoea—Betamethasone—ankylosing spondylitis	0.00034	0.00341	CcSEcCtD
Carfilzomib—PSMB10—Disease—HLA-A—ankylosing spondylitis	0.000332	0.000781	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—HLA-A—ankylosing spondylitis	0.00033	0.000777	CbGpPWpGaD
Carfilzomib—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.00033	0.0033	CcSEcCtD
Carfilzomib—PSMB10—Immune System—TLR4—ankylosing spondylitis	0.000329	0.000774	CbGpPWpGaD
Carfilzomib—Dizziness—Dexamethasone—ankylosing spondylitis	0.000329	0.0033	CcSEcCtD
Carfilzomib—Dizziness—Betamethasone—ankylosing spondylitis	0.000329	0.0033	CcSEcCtD
Carfilzomib—PSMB9—Immune System—TLR4—ankylosing spondylitis	0.000327	0.00077	CbGpPWpGaD
Carfilzomib—Insomnia—Methotrexate—ankylosing spondylitis	0.000327	0.00328	CcSEcCtD
Carfilzomib—Nausea—Triamcinolone—ankylosing spondylitis	0.000325	0.00326	CcSEcCtD
Carfilzomib—Nausea—Methylprednisolone—ankylosing spondylitis	0.000325	0.00326	CcSEcCtD
Carfilzomib—Dyspnoea—Methotrexate—ankylosing spondylitis	0.000322	0.00323	CcSEcCtD
Carfilzomib—Vomiting—Betamethasone—ankylosing spondylitis	0.000316	0.00317	CcSEcCtD
Carfilzomib—Vomiting—Dexamethasone—ankylosing spondylitis	0.000316	0.00317	CcSEcCtD
Carfilzomib—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000314	0.00315	CcSEcCtD
Carfilzomib—Fatigue—Methotrexate—ankylosing spondylitis	0.000312	0.00313	CcSEcCtD
Carfilzomib—Headache—Betamethasone—ankylosing spondylitis	0.000311	0.00312	CcSEcCtD
Carfilzomib—Headache—Dexamethasone—ankylosing spondylitis	0.000311	0.00312	CcSEcCtD
Carfilzomib—PSMB2—Immune System—IL1A—ankylosing spondylitis	0.000311	0.000732	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL1A—ankylosing spondylitis	0.000311	0.000732	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL1A—ankylosing spondylitis	0.000311	0.000732	CbGpPWpGaD
Carfilzomib—Asthenia—Prednisone—ankylosing spondylitis	0.000311	0.00311	CcSEcCtD
Carfilzomib—Pain—Methotrexate—ankylosing spondylitis	0.000309	0.0031	CcSEcCtD
Carfilzomib—PSMB5—Immune System—CD40LG—ankylosing spondylitis	0.000309	0.000727	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CD40LG—ankylosing spondylitis	0.000309	0.000727	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CD40LG—ankylosing spondylitis	0.000309	0.000727	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL1A—ankylosing spondylitis	0.000307	0.000721	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CD40LG—ankylosing spondylitis	0.000305	0.000717	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000299	0.000703	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000299	0.000703	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000299	0.000703	CbGpPWpGaD
Carfilzomib—Diarrhoea—Prednisone—ankylosing spondylitis	0.000296	0.00297	CcSEcCtD
Carfilzomib—Nausea—Betamethasone—ankylosing spondylitis	0.000295	0.00296	CcSEcCtD
Carfilzomib—Nausea—Dexamethasone—ankylosing spondylitis	0.000295	0.00296	CcSEcCtD
Carfilzomib—PSMB8—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000294	0.000693	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HLA-B—ankylosing spondylitis	0.000294	0.000692	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HLA-B—ankylosing spondylitis	0.000294	0.000692	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HLA-B—ankylosing spondylitis	0.000294	0.000692	CbGpPWpGaD
Carfilzomib—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	0.000292	0.000686	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HLA-B—ankylosing spondylitis	0.00029	0.000682	CbGpPWpGaD
Carfilzomib—PSMB8—Betamethasone—Methylprednisolone—ankylosing spondylitis	0.000288	0.0106	CbGdCrCtD
Carfilzomib—PSMB8—Dexamethasone—Methylprednisolone—ankylosing spondylitis	0.000288	0.0106	CbGdCrCtD
Carfilzomib—Dizziness—Prednisone—ankylosing spondylitis	0.000286	0.00287	CcSEcCtD
Carfilzomib—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000286	0.00287	CcSEcCtD
Carfilzomib—PSMB8—Betamethasone—Dexamethasone—ankylosing spondylitis	0.000284	0.0104	CbGdCrCtD
Carfilzomib—PSMB8—Dexamethasone—Betamethasone—ankylosing spondylitis	0.000284	0.0104	CbGdCrCtD
Carfilzomib—PSMB10—Signaling Pathways—MMP3—ankylosing spondylitis	0.000281	0.00066	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MMP3—ankylosing spondylitis	0.000279	0.000657	CbGpPWpGaD
Carfilzomib—PSMB8—Dexamethasone—Triamcinolone—ankylosing spondylitis	0.000277	0.0102	CbGdCrCtD
Carfilzomib—PSMB8—Betamethasone—Triamcinolone—ankylosing spondylitis	0.000277	0.0102	CbGdCrCtD
Carfilzomib—Vomiting—Prednisone—ankylosing spondylitis	0.000275	0.00276	CcSEcCtD
Carfilzomib—PSMB5—Immune System—HLA-A—ankylosing spondylitis	0.000272	0.000641	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HLA-A—ankylosing spondylitis	0.000272	0.000641	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HLA-A—ankylosing spondylitis	0.000272	0.000641	CbGpPWpGaD
Carfilzomib—Headache—Prednisone—ankylosing spondylitis	0.000271	0.00272	CcSEcCtD
Carfilzomib—PSMB8—Immune System—HLA-A—ankylosing spondylitis	0.000269	0.000632	CbGpPWpGaD
Carfilzomib—PSMB8—Betamethasone—Prednisone—ankylosing spondylitis	0.000263	0.00967	CbGdCrCtD
Carfilzomib—PSMB8—Dexamethasone—Prednisone—ankylosing spondylitis	0.000263	0.00967	CbGdCrCtD
Carfilzomib—PSMB5—Immune System—CRP—ankylosing spondylitis	0.00026	0.000612	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CRP—ankylosing spondylitis	0.00026	0.000612	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CRP—ankylosing spondylitis	0.00026	0.000612	CbGpPWpGaD
Carfilzomib—Asthenia—Methotrexate—ankylosing spondylitis	0.00026	0.0026	CcSEcCtD
Carfilzomib—Nausea—Prednisone—ankylosing spondylitis	0.000257	0.00258	CcSEcCtD
Carfilzomib—PSMB8—Dexamethasone—Prednisolone—ankylosing spondylitis	0.000257	0.00944	CbGdCrCtD
Carfilzomib—PSMB8—Betamethasone—Prednisolone—ankylosing spondylitis	0.000257	0.00944	CbGdCrCtD
Carfilzomib—PSMB8—Immune System—CRP—ankylosing spondylitis	0.000256	0.000603	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—HLA-A—ankylosing spondylitis	0.000252	0.000592	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—HLA-A—ankylosing spondylitis	0.000252	0.000592	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—HLA-A—ankylosing spondylitis	0.000252	0.000592	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—TLR4—ankylosing spondylitis	0.000249	0.000586	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—TLR4—ankylosing spondylitis	0.000249	0.000586	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—TLR4—ankylosing spondylitis	0.000249	0.000586	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—HLA-A—ankylosing spondylitis	0.000248	0.000584	CbGpPWpGaD
Carfilzomib—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000247	0.00248	CcSEcCtD
Carfilzomib—PSMB8—Immune System—TLR4—ankylosing spondylitis	0.000246	0.000578	CbGpPWpGaD
Carfilzomib—Dizziness—Methotrexate—ankylosing spondylitis	0.000239	0.0024	CcSEcCtD
Carfilzomib—Vomiting—Methotrexate—ankylosing spondylitis	0.00023	0.00231	CcSEcCtD
Carfilzomib—Headache—Methotrexate—ankylosing spondylitis	0.000227	0.00227	CcSEcCtD
Carfilzomib—Nausea—Methotrexate—ankylosing spondylitis	0.000215	0.00215	CcSEcCtD
Carfilzomib—PSMB5—Signaling Pathways—MMP3—ankylosing spondylitis	0.000213	0.0005	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MMP3—ankylosing spondylitis	0.000213	0.0005	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MMP3—ankylosing spondylitis	0.000213	0.0005	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MMP3—ankylosing spondylitis	0.00021	0.000493	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	0.000153	0.00036	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000144	0.000339	CbGpPWpGaD
